Wall Street analysts predict that BioLife Solutions Inc (NASDAQ:BLFS) will report earnings per share (EPS) of $0.02 for the current fiscal quarter, Zacks reports. Two analysts have made estimates for BioLife Solutions’ earnings. BioLife Solutions posted earnings of $0.05 per share during the same quarter last year, which suggests a negative year over year growth rate of 60%. The company is expected to announce its next quarterly earnings results on Thursday, August 8th.
On average, analysts expect that BioLife Solutions will report full-year earnings of $0.13 per share for the current financial year, with EPS estimates ranging from $0.11 to $0.15. For the next financial year, analysts forecast that the business will post earnings of $0.30 per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow BioLife Solutions.
BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported $0.03 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.03. The firm had revenue of $5.77 million during the quarter, compared to analysts’ expectations of $5.67 million. BioLife Solutions had a return on equity of 10.32% and a net margin of 17.01%.
In other news, CEO Michael Rice sold 7,088 shares of BioLife Solutions stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $17.19, for a total value of $121,842.72. Following the completion of the sale, the chief executive officer now owns 182,102 shares of the company’s stock, valued at $3,130,333.38. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Andrew G. Hinson sold 6,000 shares of BioLife Solutions stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $17.50, for a total value of $105,000.00. Following the completion of the sale, the director now directly owns 33,747 shares of the company’s stock, valued at approximately $590,572.50. The disclosure for this sale can be found here. Insiders have sold 166,787 shares of company stock valued at $2,989,057 in the last three months. 38.50% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the company. Cowen Prime Services LLC purchased a new stake in shares of BioLife Solutions in the first quarter valued at $63,000. Ladenburg Thalmann Financial Services Inc. grew its position in shares of BioLife Solutions by 281.3% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,380 shares of the medical equipment provider’s stock valued at $96,000 after purchasing an additional 3,969 shares during the period. Canton Hathaway LLC acquired a new position in BioLife Solutions in the fourth quarter valued at $66,000. Signaturefd LLC acquired a new position in BioLife Solutions in the first quarter valued at $161,000. Finally, Morgan Stanley boosted its holdings in BioLife Solutions by 114.8% in the first quarter. Morgan Stanley now owns 9,793 shares of the medical equipment provider’s stock valued at $175,000 after acquiring an additional 5,234 shares during the last quarter. 45.76% of the stock is owned by institutional investors and hedge funds.
BLFS stock traded down $0.05 during midday trading on Friday, hitting $18.46. 158,904 shares of the stock were exchanged, compared to its average volume of 160,173. The stock has a market cap of $347.99 million, a PE ratio of 133.29 and a beta of 1.46. BioLife Solutions has a fifty-two week low of $9.15 and a fifty-two week high of $26.35. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.99 and a current ratio of 14.50.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
Recommended Story: What is a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.